68 results about "Bipolar mood disorder" patented technology

The present disclosure relates to novel lamotrigine salts, co-crystals, and compositions. In some embodiments, the lamotrigine salt is a lamotrigine dicarboxylic acid salt or hydrate or solvate thereof. In some embodiments, the lamotrigine co-crystal is a co-crystal of lamotrigine and a dicarboxylic acid, or a hydrate or solvate thereof. In some embodiments, the compositions comprise lamotrigine or a salt or co-crystal thereof, or a hydrate or solvate thereof. In some embodiments, the composition is in the form of a powder. In some embodiments, the composition is in the form of a liquid. The present disclosure also relates to methods of preparation and use in medical therapy, for example, for the treatment of a subject with epilepsy or bipolar disorder.

The invention relates to the technical field of disease animal models, in particular to a construction method, an evaluation method and application of a bipolar affective disorder liver stagnation and spleen deficiency syndrome combined animal model. According to the method, a liver depression and spleen deficiency syndrome modeling method is adopted for model construction, evaluation indexes are formulated by combining manic and depression behavior expressions of mice and innovatively combining typical expressions of liver depression and spleen deficiency, a liver depression and spleen deficiency syndrome animal model evaluation method is explored, and a thought is provided for achieving standardization and normalization of liver depression and spleen deficiency syndrome model evaluation. The modeling method is simple and economical, provides an experimental animal model for syndrome differentiation treatment of diseases, particularly provides a corresponding animal model for traditional Chinese medicine syndrome differentiation treatment and new drug pharmacological experiments, accelerates the progress of traditional Chinese medicine disease syndrome research and new drug development, provides technical service for drug evaluation, and has great application value.

The present invention relates to Compound 1 for the use in the treatment of Major Depressive Disorder, Treatment-resistant Depression, Bipolar Depressive Disorder, Depressive Episodes associated with Bipolar disorders, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, and / or Borderline Personality Disorder, chemical synthesis of Compound 1, polymorphs of Compound 1, and pharmaceutical compositions comprising Compound 1 and / or its polymorphs.

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The invention relates to a urine protein marker for depression and bipolar affective disorder and application of the urine protein marker in early diagnosis. Specifically, the invention relates to application of a reagent for detecting the content of protein in urine of a subject in preparation of a reagent for diagnosing depression and bipolar affective disorder, and the protein in the urine is selected from the following combinations: Uniprot ID: P11766, H7BY57, O95967, O95433, K7ELM9, P15328 and P68371.

The present invention relates to the use of agomelatine (or its prodrugs or salts) in the treatment of major depressive disorder or bipolar disorder, including the selection of patients who would benefit most from agomelatine.

This invention discloses a method for isolating and extracting *Havnia vesicularis* using penicillin and vancomycin. The method mainly includes the following steps: inclusion and screening of patients with bipolar disorder; collection and processing of feces from these patients; isolation and treatment of *Havnia vesicularis* by adding penicillin and vancomycin to the feces; and identification of *Havnia vesicularis*. This invention improves the isolation efficiency and success rate of *Havnia vesicularis*, solving the problems of low isolation efficiency and poor identification accuracy in existing technologies.

The application provides a model training method and a bipolar disorder personalized treatment dialogue generation method and device, belonging to the technical field of deep learning, aiming at the problems that the current diagnosis accuracy of bipolar mood disorder is not high and the matching of treatment dialogue with patients is poor, the model training can be performed on a multi-modal language model according to a voice signal with significant characteristics of bipolar mood disorder, and a target classification model for bipolar mood disorder classification is obtained. Since the voice signal contains characteristics such as semantics, tone, pronunciation rhythm and other characteristics directly related to bipolar mood disorder expressed by the patient, the target classification model can be used for accurate classification of bipolar mood disorder, and when the target classification model is used for classification of bipolar mood disorder, the excessive dependence on the subjective diagnosis of doctors can be avoided, and the accuracy of the classification prediction of bipolar mood disorder is effectively improved.

Disclosed are a heterocycloalkyl carboxylic acid derivative, an intermediate, a preparation method therefor, and a use thereof, relating to the technical field of pharmaceutical chemistry. The heterocycloalkyl carboxylic acid derivative of the present invention is a compound represented by formula (I) below, or a stereoisomer, geometric isomer, tautomer, N-oxide, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof. By means of in vitro activity detection and animal behavioral experiments, it has been proven that said compound has good therapeutic effects for neurological diseases such as depression and bipolar disorder, as well as metabolic diseases such as diabetes and metabolic disorders.

A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

The invention discloses a heterocyclic alkyl carboxylic acid derivative, an intermediate and a preparation method and application thereof, and relates to the technical field of medicinal chemistry. The heterocycloalkyl carboxylic acid derivative is a compound as shown in the following formula, and a stereoisomer, a geometric isomer, a tautomer, nitrogen oxide, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the heterocycloalkyl carboxylic acid derivative, and in-vitro activity detection and animal behavioral experiments prove that the compound has good treatment effect on neurological diseases, neurological diseases, neurological diseases, neurological diseases, neurological diseases, neurological diseases, neurological diseases, neurological diseases, neurological diseases and neurological diseases. The traditional Chinese medicine composition has a good treatment effect on diseases such as depression, bidirectional affective disorder and the like, and metabolic diseases such as diabetes mellitus, metabolic disorder and the like.

The invention provides an image processing method and an image processing device, and relates to the field of computers. According to the method, feature extraction is carried out on multi-modal image data of functional magnetic resonance image data and structural magnetic resonance image data of a brain, feature fusion is carried out, classification is carried out based on fused features, an image recognition result is obtained, feature extraction is carried out based on a channel attention and space attention decoupling method, and the recognition accuracy is improved. According to the method, the image features can be extracted more accurately, the accuracy of the image recognition result is further improved, and diagnosis of mental diseases such as bidirectional affective disorder and Alzheimer's disease can be better assisted.

This invention discloses a method for identifying unipolar and bipolar depression based on deep learning-based multi-state EEG fusion, comprising: Step 1, performing continuous wavelet transform on EEG signals in open and closed states respectively to obtain open-eye time-frequency maps and closed-eye time-frequency maps; Step 2, using a deep learning model to extract features from the open-eye and closed-eye time-frequency maps obtained in Step 1 to obtain feature vectors for open-eye and closed-eye states; then, fusing the feature vectors in open-eye and closed-eye states to obtain a multi-state fused feature vector; finally, using a deep learning classification network to classify and identify the multi-state fused feature vector to obtain the identification result, thus completing the identification. This invention uses a deep learning model based on EEG signals to perform three-class classification identification of unipolar depression, bipolar disorder, and healthy individuals, improving classification performance.

Combination compositions of Compound 1 and fesoterodine for use in the treatment of neurological disorders, such as schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia, are described.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

The present invention provides combinations of biomarkers that can be used in the diagnosis and differentiation of bipolar disorder and schizophrenia. The present invention therefore provides methods of differentiating, diagnosing and treating bipolar disorder and schizophrenia, by examining relevant proteins and RNA in a patient sample.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

The invention relates to the technical field of computers, and discloses a bipolar disorder group determination method, device and equipment, and the method comprises the steps: obtaining multi-modal data of a to-be-detected object, the multi-modal data being used for describing biological characteristics of the to-be-detected object; performing feature extraction on the multi-modal data to obtain extracted features; performing feature interaction enhancement on the extracted features to obtain features after interaction enhancement; carrying out feature fusion on the interactive enhanced features to obtain fused features; the fused features are mapped to obtain a classification result of the to-be-detected object, and the classification result is used for indicating whether the to-be-detected object belongs to a bipolar disorder group or not and indicating a corresponding bipolar disorder phase state when the to-be-detected object is judged to be the bipolar disorder group. According to the method and the device, the to-be-detected object is subjected to two-phase obstacle recognition based on the multi-modal data, so that the accuracy of two-phase obstacle group and two-phase obstacle phase state recognition can be improved.

Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The present invention relates to a method for differential diagnosis of bipolar and monophasic disorders in a human patient during a depressive period from a biological sample of said patient, the method comprising at least determining the relative proportion of RNA editing variants of the A to I editing RNA ZNF267 gene. The invention also relates to a method for monitoring the treatment of a depressive patient exhibiting a bipolar disorder or a monophasic disorder. Finally, the present invention provides a kit for differential diagnosis of bipolar disorder and monophasic disorder in a patient during the depressive phase.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

There is provided bacterial compositions for treatment of bipolar disorder or symptoms thereof and methods of treating bipolar disorders or symptoms there of using the same. The compositions comprise a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides.

Novel tryptamine compounds according to Formulas (1), (2), (3), (4), (5), and (6) and sub-formulas thereof, pharmaceutical salts thereof, and pharmaceutical compositions thereof, and methods of treating mood disorders, including depressive disorders and bipolar disorders, comprising administering a therapeutically effective amount of a compound according to any one of Formulas (1), (2), (3), (4), (5), and (6) or a pharmaceutical composition thereof to a subject in need thereof.

The present application relates to a compound as shown in formula (I), stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, and preparation method and pharmaceutical composition. The compound is an NK-3 receptor antagonist, which can be used for preventing and / or treating depression, anxiety, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory disease, vomiting, preeclampsia, airway related disease, reproductive disorder, contraception and sex hormone dependent disease, gynecological disease related disease, menopausal syndrome related disease.

The invention provides application of a chalcone compound as well as a stereoisomer, a pharmaceutically acceptable salt or a solvate thereof in preparation of a medicament for treating depression. The depression is selected from mild depression, moderate depression, severe depression, persistent depressive disorder, depression associated with bipolar disorder, seasonal affective disorder, psychotic depression, postpartum depression, premenstrual anxiety disorder, encountering depression, pleasant sensation deficiency, melancholia, middle-year depression and late-year depression; depression caused by identifiable pressure factors, refractory depression, or a combination thereof. The compounds can treat mental symptoms of depression, such as depressive mood and loss of interest or fun in almost all activities.

Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.